Clinical Trials in the EU / 2025-521711-39-00
Authorised, recruiting
Phase III
A 52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)
2025-521711-39-00 · tracked via the Priya Life Science EU tracker
Condition studied
Lewy body Dementia psychosis (LBDP)
Eligibility
Primary endpoint
Treatment-emergent adverse events (TEAEs)
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View 2025-521711-39-00 on CTIS ↗ ← All trials in the EU